When it comes to drug discovery not all Gram-negative bacterial biodefence pathogens are created equal: Burkholderia pseudomallei is different

Microbial Biotechnology

Volumn 5, Issue 5, 2012, Pages 581-583

  Schweizer, Herbert P ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BAL 30072; CEFTAZIDIME; CETHROMYCIN; CHLORAMPHENICOL; COLISTIN; GENTAMICIN; IMIPENEM; MEROPENEM; TRIMETHOPRIM; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL OUTER MEMBRANE; BACTERIAL STRAIN; BURKHOLDERIA PSEUDOMALLEI; GENE DELETION; GRAM NEGATIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR MECHANICS; NONHUMAN;

ANTI-BACTERIAL AGENTS; BIOLOGICAL WARFARE AGENTS; BURKHOLDERIA PSEUDOMALLEI; CELL WALL; COLISTIN; DRUG DISCOVERY; DRUG RESISTANCE, BACTERIAL; MODELS, BIOLOGICAL;

BACTERIA (MICROORGANISMS); BURKHOLDERIA PSEUDOMALLEI; NEGIBACTERIA;

EID: 84862897941     PISSN: 17517907     EISSN: 17517915     Source Type: Journal    
DOI: 10.1111/j.1751-7915.2012.00334.x     Document Type: Article

References (20)

1. Brett, P.J., DeShazer, D., and Woods, D.E. (1998) Burkholderia thailandensis sp. nov., a Burkholderia pseudomallei-like species. Int J Syst Bacteriol 48: 317-320.
2. DeShazer, D., Brett, P., Carlyon, R., and Woods, D. (1997) Mutagenesis of Burkholderia pseudomallei with Tn5-OT182: isolation of motility mutants and molecular characterization of the flagellin structural gene. J Bacteriol 179: 2116-2125.
3. Estes, D.M., Dow, S.W., Schweizer, H.P., and Torres, A.G. (2010) Present and future therapeutic strategies for melioidosis and glanders. Expert Rev Anti Infect Ther 8: 325-338.
4. Hancock, R.E.W. (1998) Resistance mechanisms in Pseudomonas aeruginosa and other non-fermentative bacteria. Clin Infect Dis 27 (Suppl. 1): S93-S99.
5. Kumar, A., Chua, K.-L., and Schweizer, H. (2006) Method for regulated expression of single-copy efflux pump genes in a surrogate Pseudomonas aeruginosa strain: identification of the BpeEF-OprC chloramphenicol and trimethoprim efflux pump of Burkholderia pseudomallei 1026b. Antimicrob Agents Chemother 50: 3460-3463.
6. Mima, T., and Schweizer, H. (2010) The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system. Antimicrob Agents Chemother 54: 3113-3120.
7. Mima, T., Kvitko, B.H., Rholl, D.A., Page, M.G., Desarbre, E., and Schweizer, H. (2011a) In vitro activity of BAL30072 against Burkholderia pseudomallei. Int J Antimicrob Agents 38: 157-159.
8. Mima, T., Schweizer, H., and Xu, Z.-Q. (2011b) In vitro activity of cethromycin against Burkholderia pseudomallei and investigation of mechanism of resistance. J Antimicrob Chemother 66: 73-78.
9. Moore, R.A., DeShazer, D., Reckseidler, S., Weissman, A., and Woods, D.E. (1999) Efflux-mediated aminoglycoside and macrolide resistance in Burkholderia pseudomallei. Antimicrob Agents Chemother 43: 465-470.
10. Nierman, W.C., DeShazer, D., Kim, H.S., Tettelin, H., Nelson, K.E., Feldblyum, T., etal. (2004) Structural flexibility in the Burkholderia mallei genome. Proc Natl Acad Sci USA 101: 14246-14251.
11. Nikaido, H. (2001) Preventing drug access to targets: cell surface permeability barriers and active efflux in bacteria. Semin Cell Dev Biol 12: 215-223.
12. Novem, V., Shui, G., Wang, D., Bendt, A.K., Sim, S.H., Liu, Y., etal. (2009) Structural and biological diversity of lipopolysaccharides from Burkholderia pseudomallei and Burkholderia thailandensis. Clin Vaccine Immunol 16: 1420-1428.
13. Pages, J.-M., James, C.E., and Winterhalter, M. (2008) The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria. Nat Rev Microbiol 6: 893-903.
14. Peacock, S.J., Schweizer, H., Dance, D.A.B., Smith, T.L., Gee, J.E., Wuthiekanun, V., etal. (2008) Consensus guidelines on the management of accidental laboratory exposure to Burkholderia pseudomallei and Burkholderia mallei. Emerg Infect Dis 14: e2.
15. Propst, K.L., Mima, T., Choi, K.H., Dow, S.W., and Schweizer, H. (2010) A Burkholderia pseudomallei ΔpurM mutant is avirulent in immune competent and immune deficient animals: candidate strain for exclusion from Select Agent lists. Infect Immun 78: 3136-3143.
16. Raetz, C.R., Reynolds, C.M., Trent, M.S., and Bishop, R.E. (2007) Lipid A modification systems in gram-negative bacteria. Annu Rev Biochem 76: 295-329.
17. Trunck, L.A., Propst, K.L., Wuthiekanun, V., Tuanyok, A., Beckstrom-Sternberg, S.M., Beckstrom-Sternberg, J.S., etal. (2009) Molecular basis of rare aminoglycoside susceptibility and pathogenesis of Burkholderia pseudomallei clinical isolates from Thailand. PLoS Negl Trop Dis 3: e519.
18. Walsh, C. (2003) Antibiotic Resistance. Washington, DC, USA: American Society for Microbiology Press.
19. Wuthiekanun, V., and Peacock, S.J. (2006) Management of melioidosis. Expert Rev Anti Infect Ther 4: 445-455.
20. Yu, Y., Kim, H.S., Chua, H.H., Lin, C.H., Sim, S.H., Lin, D., etal. (2006) Genomic patterns of pathogen evolution revealed by comparison of Burkholderia pseudomallei, the causative agent of melioidosis, to avirulent Burkholderia thailandensis. BMC Microbiol 6: 46.